Isomorphic Labs Raises $2.1B to Scale AI Drug Design Engine
Isomorphic Labs secured $2.1B in Series B funding led by Thrive Capital alongside Alphabet, GV, MGX, Temasek, Abu Dhabi’s SWF, CapitalG and the UK Sovereign AI Fund. The capital will scale its IsoDDE AI drug design engine, grow headcount from 350, and drive candidates toward clinical trials by late 2026.
1. Funding Round Overview
Isomorphic Labs closed a $2.1 billion Series B round led by Thrive Capital, with participation from Alphabet, GV, MGX, Temasek, Abu Dhabi’s sovereign wealth fund, CapitalG and the UK Sovereign AI Fund. The round’s valuation remains undisclosed, marking the spinout’s second major funding after a $600 million Series A in 2025.
2. Technology and Pipeline Expansion
The new funding will accelerate development of the IsoDDE AI drug design engine and support hiring across its sites in London, Cambridge, Massachusetts and Lausanne. Headcount will expand beyond the current 350 employees to strengthen research, development and preclinical testing capabilities.
3. Revised Clinical Trial Timeline
The company now targets entering human clinical trials by late 2026, pushing past its initial end-2025 goal after clarifying that its first assets are in preclinical testing. Founder Sir Demis Hassabis emphasized the shift reflects a refined understanding of trial phases rather than a setback in technology readiness.
4. Partnerships and Future Structure
Since its 2021 spinout from DeepMind, Isomorphic Labs has collaborated with Novartis, Eli Lilly and Johnson & Johnson on AI-driven drug discovery. Management has not ruled out a full separation from Alphabet in the future to support independent growth and strategic partnerships.